A Post-Market Clinical Evaluation of the Treatment of Tibia Fractures With the T2 Alpha Tibia Nailing System

Completed

Brief Summary: This investigation is a prospective, multi-center clinical investigation. It is anticipated that a total of 80 subjects will be enrolled. Neither subjects nor investigators are blinded to treatment and the clinical investigation includes a historical control which will be compared to the T2 Alpha Tibia Nailing System.

Total duration of enrollment, 12 month follow-up and analysis is expected to take 31 months. The clinical investigation has been designed to follow the surgeon's standard of care for tibia fractured subjects, in addition to a 12 month follow-up visit.

The primary endpoint of this clinical investigation is to confirm efficacy/performance at 12 months, as measured by the SF-36 Physical Component Summary (PCS). Confirmation of efficacy/performance at 12 months will be based on an equal or higher (non-inferior) SF-36 Physical Component Summary (PCS) result of the T2 Alpha Tibia Nailing System compared to the benchmark literature.

Detailed Description: The objective of this clinical investigation is to demonstrate the safety and efficacy/performance of the T2 Alpha Tibia Nailing System. Efficacy/performance of the procedure will be measured by an equal or higher (non-inferior) SF-36 Physical Component Summary (PCS) score result of the T2 Alpha Tibia Nailing System compared to the T2 Tibia benchmark literature at 12 months.

In addition, demonstration of bone consolidation in correct alignment will be measured by Investigator assessment by 12 months. Safety of the T2 Alpha Tibia Nailing System will be demonstrated through reporting of device related intra-operative and post-operative Adverse Events/incidents by 12 months.

Recruitment & Eligibility

Inclusion Criteria

Subject is a male or non-pregnant female age 18 years or older at the time of surgery;
Subject is willing and able to give written informed consent and comply with the requirements of this Clinical Investigation Plan;
Subject is intended to be, treated with the Tibial Nail of the T2 Alpha Tibia Nailing System in accordance with the following legally cleared/ approved Indications for Use:

Indications for Use approved In United States and Canada include:

Exclusion Criteria

Subject is currently enrolled in or plans to enroll in any concurrent drug and/or device clinical investigation that, in the opinion of the Investigator, may confound results;
Per the Investigator, the subject is in poor general health or undergoing any concurrent disease that would place the subject in excessive risk to surgery (i.e. significant circulatory problems, cardiac disease).

Arm && Interventions

Group	Intervention	Description
T2 Alpha Tibia	T2 Alpha Tibia Nailing System	Subjects in the clinical investigation will undergo placement of the Tibial Nail of the T2 Alpha Tibia Nailing System, according to the approved Instructions for Use and Operative Technique Manual.

Primary Outcome Measures

Name	Time	Method
SF-36 PCS (36-Item Short Form Health Survey Physical Component Summary)	12 months	The primary endpoint of this clinical investigation is to confirm efficacy/performance at 12 months, as measured by the SF-36 PCS (36-Item Short Form Health Survey Physical Component Summary). The SF-36 PCS is a self-report measure of health status. SF-36 Physical Component Summary scores range from 0 to 100; higher SF-36 score results are linked to better subject results. Confirmation of efficacy/performance at 12 months will be based on an equal or higher (non-inferior) SF-36 Physical Component Summary (PCS) result of the T2 Alpha Tibia Nailing System compared to the T2 Tibia benchmark literature.

Secondary Outcome Measures

Name	Time	Method
Safety Will be Measured by Capturing the Incidence Rate of Device-related Adverse Events	12 months	Incidence of device-related adverse events will be monitored by 12 months through data collection and analyses.
Efficacy/Performance Will be Measured by Demonstration of Bone Consolidation	12 months	Bone consolidation will be assessed by 12 months as measured by Investigator assessment.

Locations (4): Inova Fairfax Medical Campus
🇺🇸
Falls Church, Virginia, United States
New York University
🇺🇸
New York, New York, United States
St. Cloud Orthopedic Associates, Ltd
🇺🇸
Sartell, Minnesota, United States
UC Health
🇺🇸
Cincinnati, Ohio, United States